Gyre Therapeutics INC

Gyre Therapeutics announced on July 10, 2026, the appointment of three new directors to its board, effective August 1, 2026. Dr. Yue Xiong was named a Class I director, Maxwell Kirkby a Class II director (also joining the Compensation Committee), and Dr. Claire Weston a Class III director (joining the Audit Committee). Kirkby and Weston will each receive stock options for 40,000 shares vesting over three years and standard cash director compensation; Xiong, already the Chief Scientific Officer, receives no additional pay for board service. The company also filed a Regulation FD disclosure (Item 7.01) with no further details provided.

In this 8-K amendment, Gyre Therapeutics includes Cullgen’s financial statements for the first quarter of 2026 and full year 2025, along with unaudited pro forma combined balance sheet and income statement for those periods. This gives a more complete picture of the combined finances following the Cullgen acquisition.